Axsome Therapeutics, Inc. (AXSM)Â
Largest Insider Buys in Sector
AXSM Stock Price History Chart
AXSM Stock Performance
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Activity of Axsome Therapeutics, Inc.
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $9.66M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $242,389 and sold $5.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.
List of Insider Buy and Sell Transactions, Axsome Therapeutics, Inc.
| 2024-09-11 | Sale | director | 11,016 0.0226% | $91.31 | $1.01M | +0.48% | ||
| 2024-08-09 | Sale | Chief Operating Officer | 47,739 0.1009% | $84.26 | $4.02M | +9.18% | ||
| 2024-05-29 | Sale | director | 5,248 0.011% | $75.14 | $394,333 | +18.10% | ||
| 2024-05-29 | Sale | Chief Operating Officer | 7,910 0.0165% | $74.31 | $587,813 | +18.10% | ||
| 2024-05-28 | Sale | director | 5,249 0.0108% | $75.21 | $394,775 | +15.57% | ||
| 2024-04-01 | Sale | Chief Operating Officer | 24,662 0.0522% | $77.24 | $1.9M | +11.08% | ||
| 2024-03-15 | Sale | director | 2,347 0.0047% | $71.61 | $168,062 | +12.42% | ||
| 2024-03-14 | Sale | director | 16,976 0.036% | $69.70 | $1.18M | +21.68% | ||
| 2023-09-15 | Sale | director | 29,588 0.0626% | $75.18 | $2.22M | -0.49% | ||
| 2021-11-19 | director | 3,950 0.0109% | $37.30 | $147,350 | +3.44% | |||
| 2021-11-18 | director | 1,430 0.0037% | $35.09 | $50,181 | +4.03% | |||
| 2021-11-18 | CHIEF FINANCIAL OFFICER | 955 0.0025% | $35.26 | $33,676 | +4.03% | |||
| 2021-11-17 | director | 3,300 0.0087% | $34.52 | $113,922 | +7.00% | |||
| 2021-05-12 | director | 500 0.0014% | $58.15 | $29,075 | -38.38% | |||
| 2020-06-29 | director | 650 0.0018% | $78.50 | $51,025 | -5.10% | |||
| 2020-06-29 | Chief Financial Officer | 777 0.0021% | $76.64 | $59,549 | -5.10% | |||
| 2019-09-26 | Chief Financial Officer | 2,180 0.0063% | $24.80 | $54,064 | +210.19% | |||
| 2019-06-26 | director | 15,800 0.0481% | $23.10 | $364,980 | +145.30% | |||
| 2019-06-25 | director | 400 0.0011% | $23.25 | $9,300 | +126.86% | |||
| 2019-06-11 | Chief Financial Officer | 1,920 0.0057% | $20.80 | $39,936 | +117.89% |
Insider Historical Profitability
| JEFFS ROGER | director | 120756 0.2492% | $91.94 | 1 | 2 | +3.44% |
| Coleman Mark | director | 14600 0.0301% | $91.94 | 7 | 3 | +51.01% |
| Saad Mark E | director | 10002 0.0206% | $91.94 | 2 | 1 | +23.86% |
| Jacobson Mark L. | Chief Operating Officer | 5783 0.0119% | $91.94 | 0 | 3 | |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 41789 0.0862% | $91.94 | 6 | 0 | +75.66% |
| Kaye Randall | Chief Medical Officer | 6022 0.0124% | $91.94 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $358.52M | 9.46 | 4.49M | +0.07% | +$246,023.40 | 5.37 | |
| The Vanguard Group | $298.47M | 7.88 | 3.74M | +1.18% | +$3.47M | 0.01 | |
| BlackRock | $255M | 6.73 | 3.2M | -1.37% | -$3.53M | 0.01 | |
| Fairmount Funds Management LLC | $188.33M | 4.97 | 2.36M | 0% | +$0 | 20.53 | |
| Deep Track Capital Lp | $104.12M | 2.75 | 1.3M | +30.47% | +$24.32M | 0.48 | |
| Citadel Advisors LLC | $91.26M | 2.41 | 1.14M | +5.01% | +$4.35M | 0.05 | |
| Perceptive Advisors | $88.21M | 2.33 | 1.11M | +6.49% | +$5.37M | 0.06 | |
| RA Capital Management, L.P. | $79.8M | 2.11 | 1M | 0% | +$0 | 0.08 | |
| Morgan Stanley | $75.32M | 1.99 | 943,883 | +52.39% | +$25.9M | 0.01 | |
| State Street | $74.91M | 1.98 | 938,716 | +1.57% | +$1.16M | <0.01 | |
| Geode Capital Management | $67.47M | 1.78 | 845,407 | +2.81% | +$1.84M | 0.01 | |
| Fidelity Investments | $66.12M | 1.74 | 828,550 | -6.06% | -$4.27M | <0.01 | |
| Millennium Management LLC | $59.17M | 1.56 | 741,518 | -18.51% | -$13.44M | 0.04 | |
| Alethea Capital Management LLC | $59.12M | 1.56 | 740,791 | -1.5% | -$897,989.40 | 3.71 | |
| Macquarie Group | $55.89M | 1.48 | 700,410 | +2,444.72% | +$53.7M | 0.05 | |
| Bellevue Group | $54.7M | 1.44 | 685,476 | +7.89% | +$4M | 0.84 | |
| Wellington Management Company | $54M | 1.43 | 676,646 | +182.15% | +$34.86M | 0.01 | |
| Hood River Capital Management LLC | $41.56M | 1.1 | 520,750 | +32.59% | +$10.21M | 0.93 | |
| Adage Capital Partners Gp L L C | $41.1M | 1.08 | 515,000 | +41.1% | +$11.97M | 0.08 | |
| PFM Health Sciences | $37.3M | 0.98 | 467,427 | 0% | +$0 | 1.03 | |
| Avidity Partners Management Lp | $34.39M | 0.91 | 431,000 | -6.18% | -$2.27M | 1.31 | |
| Boxer Capital, LLC | $31.92M | 0.84 | 400,000 | 0% | +$0 | 0.65 | |
| Point72 Asset Management | $30.23M | 0.8 | 378,864 | -54.75% | -$36.58M | 0.04 | |
| Woodline Partners LP | $28.74M | 0.76 | 360,128 | -35.94% | -$16.12M | 0.25 | |
| Eventide Asset Management | $27.67M | 0.73 | 346,712 | 0% | +$0 | 0.45 | |
| Northern Trust | $26.82M | 0.71 | 336,085 | -2.1% | -$576,395.40 | <0.01 | |
| Jefferies Financial Group | $26.55M | 0.7 | 332,766 | -40.93% | -$18.4M | 0.46 | |
| Charles Schwab | $24.03M | 0.63 | 301,074 | +1.82% | +$428,765.40 | 0.01 | |
| Goldman Sachs | $23.27M | 0.61 | 291,612 | +41.69% | +$6.85M | <0.01 | |
| Loomis, Sayles & Company | $22.33M | 0.59 | 279,791 | New | +$22.33M | 0.03 | |
| Invesco | $19.6M | 0.52 | 245,653 | +432.14% | +$15.92M | <0.01 | |
| Nuveen | $19.59M | 0.52 | 245,527 | +4.64% | +$868,303.77 | 0.01 | |
| HERITAGE ASSET MANAGEMENT INC | $17.44M | 0.48 | 226,515 | New | +$17.44M | 0.09 | |
| Barclays | $17.56M | 0.46 | 220,098 | +14.72% | +$2.25M | 0.01 | |
| GHOST TREE CAPITAL LLC | $16.76M | 0.44 | 210,000 | +27.27% | +$3.59M | 0.23 | |
| Driehaus Capital Management LLC | $16.33M | 0.43 | 204,699 | -23% | -$4.88M | 0.16 | |
| Jane Street Capital | $15.89M | 0.42 | 199,079 | +114.45% | +$8.48M | 0.02 | |
| JPMorgan Chase | $15.58M | 0.41 | 195,261 | +2.82% | +$427,408.80 | <0.01 | |
| Bank of America | $14.82M | 0.39 | 185,713 | +5.42% | +$761,770.73 | <0.01 | |
| BNY Mellon | $12.27M | 0.32 | 153,771 | -7.53% | -$999,257.49 | <0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $11.46M | 0.3 | 143,600 | +81.54% | +$5.15M | 1.11 | |
| Affinity Asset Advisors | $11.15M | 0.29 | 139,758 | +179.52% | +$7.16M | 0.17 | |
| Altium Capital Management Lp | $11.01M | 0.29 | 138,000 | 0% | +$0 | 1.29 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $11.04M | 0.29 | 138,300 | New | +$11.04M | 0.03 | |
| U.S. Bancorp | $10.65M | 0.28 | 133,505 | -6.92% | -$791,536.20 | 0.02 | |
| Iridian Asset Management Llc Ct | $10.28M | 0.27 | 128,842 | -6.86% | -$757,701.03 | 2.02 | |
| Bioimpact Capital Llc | $9.11M | 0.24 | 114,127 | +22.21% | +$1.66M | 1.47 | |
| WCM Investment Management | $8.9M | 0.24 | 111,590 | +6.47% | +$541,203.60 | 0.02 | |
| Franklin Templeton Investments | $8.61M | 0.23 | 107,871 | +2,942.05% | +$8.33M | <0.01 | |
| Frontier Capital Management Co | $8.41M | 0.22 | 105,344 | +11.02% | +$834,388.78 | 0.08 |